Malignancies after renal transplantation during 33 years at a single center.

Standard

Malignancies after renal transplantation during 33 years at a single center. / Végso, Gyula; Tóth, Mária; Hídvégi, Márta; Toronyi, Eva; Langer, Robert M; Dinya, Elek; Tóth, András; Perner, Ferenc; Járay, Jeno.

in: PATHOL ONCOL RES, Jahrgang 13, Nr. 1, 1, 2007, S. 63-69.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Végso, G, Tóth, M, Hídvégi, M, Toronyi, E, Langer, RM, Dinya, E, Tóth, A, Perner, F & Járay, J 2007, 'Malignancies after renal transplantation during 33 years at a single center.', PATHOL ONCOL RES, Jg. 13, Nr. 1, 1, S. 63-69. <http://www.ncbi.nlm.nih.gov/pubmed/17387391?dopt=Citation>

APA

Végso, G., Tóth, M., Hídvégi, M., Toronyi, E., Langer, R. M., Dinya, E., Tóth, A., Perner, F., & Járay, J. (2007). Malignancies after renal transplantation during 33 years at a single center. PATHOL ONCOL RES, 13(1), 63-69. [1]. http://www.ncbi.nlm.nih.gov/pubmed/17387391?dopt=Citation

Vancouver

Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E et al. Malignancies after renal transplantation during 33 years at a single center. PATHOL ONCOL RES. 2007;13(1):63-69. 1.

Bibtex

@article{120b9662eed8413484303177f1c6b2d6,
title = "Malignancies after renal transplantation during 33 years at a single center.",
abstract = "This study provides an analysis of incidence and characteristics of malignant tumors of 2535 patients who underwent renal transplantation between 1973 and 2007 at the Transplantation Center in Budapest. One hundred ninety-three malignant diseases were found in 188 patients (7.6%). The incidence of thyroid-, renal- hepatic-, skin- and gastric cancers as well as of Kaposi sarcoma and lymphomas increased in our transplant patient cohort compared to the figures of the general population based on the data of our Cancer Registry. On the other hand, colorectal-, oralprostate and lung cancers were underrepresented in our patient cohort. The mean time of diagnosis of malignancies following kidney transplantation was 58.5+/-44.8 months. One fifth of the tumors were detected within the first year. Patients with malignancies were distributed into four groups based on the immunosuppressive regimen: group I (8.5%), azathioprine + prednisone; group II (59.0%), cyclosporine + prednisone; group III (26.6%), cyclosporine + mycophenolate mofetil + prednisone; group IV (5.9%), tacrolimus + mycophenolate mofetil + prednisone. The mean age of patients was 47.3, 53.5, 55.5 and 58.1 years in group I, II, III and IV, respectively. Oncologic and immunosuppressive therapy was decided individually. Immunosuppression was switched to rapamycin-containing regimens in 63 cases. We lost 92 patients (48.9%) with a mean survival time of 25.8+/-39.4 months. Cumulative 1- and 5-year survivals were 69.5% and 52%, respectively. The increasing number of cancers seen early after transplantation and the increased risk of developing a cancer due to the older age of recipients draw attention to the importance of regular oncologic screening in patients on the waiting list and after transplantation.",
author = "Gyula V{\'e}gso and M{\'a}ria T{\'o}th and M{\'a}rta H{\'i}dv{\'e}gi and Eva Toronyi and Langer, {Robert M} and Elek Dinya and Andr{\'a}s T{\'o}th and Ferenc Perner and Jeno J{\'a}ray",
year = "2007",
language = "Deutsch",
volume = "13",
pages = "63--69",
journal = "PATHOL ONCOL RES",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

RIS

TY - JOUR

T1 - Malignancies after renal transplantation during 33 years at a single center.

AU - Végso, Gyula

AU - Tóth, Mária

AU - Hídvégi, Márta

AU - Toronyi, Eva

AU - Langer, Robert M

AU - Dinya, Elek

AU - Tóth, András

AU - Perner, Ferenc

AU - Járay, Jeno

PY - 2007

Y1 - 2007

N2 - This study provides an analysis of incidence and characteristics of malignant tumors of 2535 patients who underwent renal transplantation between 1973 and 2007 at the Transplantation Center in Budapest. One hundred ninety-three malignant diseases were found in 188 patients (7.6%). The incidence of thyroid-, renal- hepatic-, skin- and gastric cancers as well as of Kaposi sarcoma and lymphomas increased in our transplant patient cohort compared to the figures of the general population based on the data of our Cancer Registry. On the other hand, colorectal-, oralprostate and lung cancers were underrepresented in our patient cohort. The mean time of diagnosis of malignancies following kidney transplantation was 58.5+/-44.8 months. One fifth of the tumors were detected within the first year. Patients with malignancies were distributed into four groups based on the immunosuppressive regimen: group I (8.5%), azathioprine + prednisone; group II (59.0%), cyclosporine + prednisone; group III (26.6%), cyclosporine + mycophenolate mofetil + prednisone; group IV (5.9%), tacrolimus + mycophenolate mofetil + prednisone. The mean age of patients was 47.3, 53.5, 55.5 and 58.1 years in group I, II, III and IV, respectively. Oncologic and immunosuppressive therapy was decided individually. Immunosuppression was switched to rapamycin-containing regimens in 63 cases. We lost 92 patients (48.9%) with a mean survival time of 25.8+/-39.4 months. Cumulative 1- and 5-year survivals were 69.5% and 52%, respectively. The increasing number of cancers seen early after transplantation and the increased risk of developing a cancer due to the older age of recipients draw attention to the importance of regular oncologic screening in patients on the waiting list and after transplantation.

AB - This study provides an analysis of incidence and characteristics of malignant tumors of 2535 patients who underwent renal transplantation between 1973 and 2007 at the Transplantation Center in Budapest. One hundred ninety-three malignant diseases were found in 188 patients (7.6%). The incidence of thyroid-, renal- hepatic-, skin- and gastric cancers as well as of Kaposi sarcoma and lymphomas increased in our transplant patient cohort compared to the figures of the general population based on the data of our Cancer Registry. On the other hand, colorectal-, oralprostate and lung cancers were underrepresented in our patient cohort. The mean time of diagnosis of malignancies following kidney transplantation was 58.5+/-44.8 months. One fifth of the tumors were detected within the first year. Patients with malignancies were distributed into four groups based on the immunosuppressive regimen: group I (8.5%), azathioprine + prednisone; group II (59.0%), cyclosporine + prednisone; group III (26.6%), cyclosporine + mycophenolate mofetil + prednisone; group IV (5.9%), tacrolimus + mycophenolate mofetil + prednisone. The mean age of patients was 47.3, 53.5, 55.5 and 58.1 years in group I, II, III and IV, respectively. Oncologic and immunosuppressive therapy was decided individually. Immunosuppression was switched to rapamycin-containing regimens in 63 cases. We lost 92 patients (48.9%) with a mean survival time of 25.8+/-39.4 months. Cumulative 1- and 5-year survivals were 69.5% and 52%, respectively. The increasing number of cancers seen early after transplantation and the increased risk of developing a cancer due to the older age of recipients draw attention to the importance of regular oncologic screening in patients on the waiting list and after transplantation.

M3 - SCORING: Zeitschriftenaufsatz

VL - 13

SP - 63

EP - 69

JO - PATHOL ONCOL RES

JF - PATHOL ONCOL RES

SN - 1219-4956

IS - 1

M1 - 1

ER -